Developing a new influenza vaccine using plant-derived nanoparticles
Official title: MULTIVALENT QS-18 PROTEIN NANOPARTICLES FOR A BROADLY PROTECTIVE INFLUENZA VIRUS VACCINE
Funded at Pop Biotechnologies, INC · NIH-10933284 · Data updated 2026-11-12
This study is testing a new flu vaccine made from a plant ingredient and tiny particles to see if it can help your body fight off different types of the flu better, and it's being done first in animals like mice and ferrets before it can be used in people.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pop Biotechnologies, INC NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | September 30, 2023 |
| Project end | September 29, 2025 |
| Funding year | 2023 |
| Award (this year) | $599,806 |
| NIH project number | 75N93023C00031-0-9999-1 |
| Project ID | NIH-10933284 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would include individuals at high risk for influenza, such as the elderly or those with compromised immune systems.
✕Less likely to help
Patients who are not at risk for influenza or those who have already received a flu vaccine may not benefit from this research.
What this research studies
This research focuses on creating a novel influenza vaccine that utilizes QS-18, a plant-derived saponin, combined with advanced nanoliposome technology. The approach aims to enhance the vaccine's effectiveness by improving the immune response through the use of specific influenza virus components. The study will involve testing the vaccine's safety and efficacy in animal models, including mice and ferrets, to gather essential data for future clinical applications. By exploring the potential of this innovative vaccine formulation, the research seeks to provide a broader protective response against various strains of the influenza virus.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and broadly protective influenza vaccine, potentially reducing the incidence of flu and its complications.
How similar studies have gone: Other research has shown promise in using plant-derived adjuvants and nanotechnology for vaccine development, indicating a potential for success in this novel approach.
Where this research is happening
-
Pop Biotechnologies, INC
Buffalo, United States Active
Researchers
- Principal investigator: Singleton, Kentner — Pop Biotechnologies, INC
- Study coordinator: Singleton, Kentner
Related research
Other NIH-funded projects on the same topics.
-
Creating vaccines for influenza and other infectious diseases
This study is all about creating new vaccines to help protect people from the flu and other infections, so patients can look forward to better options for staying healthy.
-
Creating vaccines for human trials against influenza and other infectious diseases
This study is working on creating new vaccines to help protect people from flu and other infectious diseases, including those that could be used in harmful situations, so that everyone can have safer and more effective options to stay healthy.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Surveillance and preparedness for flu and other respiratory pathogens in Kenya
A US-based research grant aims to improve how Kenya detects and prepares for influenza and other respiratory diseases to protect people there and global health.
-
Enhanced Seasonal Influenza Vaccine Targeting Shared and Variable Viral Antigens
A new DNA-based influenza vaccine approach aims to provide both precise protection against circulating strains and broader defense against unexpected strains.
-
How the immune system responds to flu shots and flu infection
This project looks at how adults' immune systems react after flu shots or when they catch the flu to find why some people get better protection than others.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.